NeuroSense reports 65% death risk reduction in ALS trial Feb 18, 2026 09:05AM
NeuroSense receives Australian patent for PrimeC drug composition Feb 9, 2026 09:20AM
Noble Capital Starts NeuroSense Therapeutics Ltd. (NRSN) at Outperform Oct 14, 2025 09:46AM
D. Boral Capital Starts NeuroSense Therapeutics Ltd. (NRSN) at Buy May 12, 2025 07:08AM
Neurosense Therapeutics (NRSN) Releases Letter to Shareholders Apr 24, 2025 09:09AM


Apr 9, 2025 08:30AM Neurosense Therapeutics (NRSN) Announces Transformative Phase 2b MicroRNA Data
Apr 8, 2025 11:21AM NeuroSense Therapeutics Ltd. (NRSN) Reports FY results
Jan 6, 2025 09:02AM Neurosense Therapeutics (NRSN) Regains Nasdaq Compliance
Dec 16, 2024 08:13AM Maxim Group Downgrades NeuroSense Therapeutics Ltd. (NRSN) to Hold
Dec 11, 2024 09:25AM Neurosense Therapeutics (NRSN) Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
Dec 2, 2024 08:32AM Neurosense Therapeutics (NRSN) Announces 4M Share Offering at $1.25/sh
Nov 19, 2024 04:18PM Neurosense Therapeutics (NRSN) Files for 10M Share Offering by Selling Stockholders
Oct 28, 2024 08:30AM Neurosense Therapeutics (NRSN) Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
Oct 15, 2024 09:16AM Neurosense (NRSN) Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
Oct 9, 2024 09:02AM Neurosense Therapeutics (NRSN) to File for Early Commercialization of ALS Treatment in Canada
Sep 24, 2024 09:05AM Neurosense Therapeutics (NRSN) Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's
Sep 24, 2024 09:00AM Neurosense Therapeutics (NRSN) Regains Nasdaq Compliance
Aug 30, 2024 04:30PM Neurosense Therapeutics (NRSN) Receives Nasdaq Non-compliance Notice
Aug 7, 2024 02:00PM Neurosense Therapeutics (NRSN) Announces Private Placement with Senior Management Participation at Premium to Market Price
Aug 1, 2024 09:15AM Neurosense Therapeutics (NRSN) Reports Positive Biomarker Data from ALS Phase 2b Clinical Trial
Jul 9, 2024 09:27AM Neurosense's (NRSN) PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
Jul 1, 2024 08:07AM Neurosense Therapeutics (NRSN) Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS
Jun 21, 2024 04:30PM Neurosense Therapeutics (NRSN) Receives Delisting Notice from Nasdaq, Intends to Appeal